Journal of clinical laboratory analysis
-
J. Clin. Lab. Anal. · Jan 2011
Comparative StudyDevelopment of simultaneous detection of total prostate-specific antigen (tPSA) and free PSA with rapid bead-based immunoassay.
Prostate-specific antigen (PSA) is the most important biochemical tumor marker for the early detection of prostate cancer; however, its diagnostic specificity is low. Therefore, free PSA (fPSA) test is recommended as an adjunct to increase the specificity. However, all the current technology only allows detecting one biomarker at one time. In this study, we reported a flexible bead-based immunoassay to measure total PSA (tPSA) and fPSA simultaneously. ⋯ The bead-based platform is rapid, sensitive, and less expensive, which allows both single sample and high-throughput measurement of tPSA and fPSA over a wide range of concentrations.
-
J. Clin. Lab. Anal. · Jan 2011
Ischemia-modified albumin as a biochemical marker in children with neuroblastoma and soft tissue sarcomas.
In this study, the levels of ischemia-modified albumin (IMA) in pediatric oncology patients with soft tissue sarcomas (STSs) and neuroblastoma (NB) were analyzed. To date, there have been no studies concerning IMA in these groups of patients. Ninety-nine children with STSs and NB were analyzed from 2006 to 2009, and 30 healthy children were also enrolled in the study. ⋯ The levels of IMA in all cancer patients (mean 116.8±39.3 U/ml), in patients with STSs (mean 119.8±27.5 U/ml), and in patients with NB (mean 114.6±36.6 U/ml) were significantly higher than in the control patients (mean 87.3±38.3 U/ml; P=0.0013, 0.0066, and 0.0164, respectively). IMA levels increased before and during the treatment compared with levels in the controls. The determination of IMA levels in pediatric oncology patients with poor prognoses from STSs and NB may play an important role in predicting response to therapy and overall outcome.